Therapy Directory

Carfilzomib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Carfilzomib as a study intervention. Browse Carfilzomib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

193

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Carfilzomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 12
States / cities: Fountain Valley, California • Denver, Colorado • Plainville, Connecticut + 9 more

Conditions: Multiple Myeloma
Interventions: Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2, Cohort 3b: Carfilzomib 27 mg/m2; Drug
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Multiple Myeloma
Interventions: Alnuctamab, Pomalidomide, Daratumumab, Elotuzumab, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 19 more

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Carfilzomib, Rituximab, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulfate, Prednisone, Pegfilgrastim, Acyclovir; Drug · Biological
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: Buffalo, New York • Cleveland, Ohio

Conditions: Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Pelareorep; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Columbus, Ohio • Salt Lake City, Utah

Conditions: Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions: Carfilzomib, Irinotecan; Drug
Lead sponsor: Cancer Research and Biostatistics Clinical Trials Consortium; Network
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more

Conditions: T-cell Lymphomas, Relapsed or Refractory
Interventions: Carfilzomib, Romidepsin, Lenalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 6
States / cities: Omaha, Nebraska • Basking Ridge, New Jersey • Commack, New York + 3 more

Conditions: Smoldering Multiple Myeloma
Interventions: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: International Myeloma Foundation; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 10
States / cities: Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more

Conditions: Neuroendocrine Cancer
Interventions: Carfilzomib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 7 more

Conditions: Multiple Myeloma
Interventions: KRdD followed by auto-HCT, KRdD only; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more

Conditions: Multiple Myeloma
Interventions: POM, Steroids, PLD, CFZ, BTZ, CLA, CY; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 12
States / cities: Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 7
States / cities: Encinitas, California • West Hills, California • West Hollywood, California + 4 more

About this Carfilzomib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Carfilzomib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Carfilzomib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Carfilzomib clinical trials

Filter and sort this therapy

Live official records

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

About this Carfilzomib clinical trials directory page